Metformin, Microbiome and Protection Against Colorectal Cancer

  title={Metformin, Microbiome and Protection Against Colorectal Cancer},
  author={Georgina R. Jones and Mark P. Molloy},
  journal={Digestive Diseases and Sciences},
Metformin is widely used as a firstline therapy to improve insulin sensitivity in type 2 diabetes mellitus (T2DM) patients. This is achieved primarily through regulating AMP-activated protein kinase (AMPK)-dependent pathways leading to reduced hepatic gluconeogenesis and improved muscular uptake of glucose. Epidemiological studies first recognized a relationship with metformin use in T2DM patients and reduced colorectal cancer (CRC) risk. Thereafter, metformin has gained wide attention as a… Expand

Figures and Tables from this paper

Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend
It was concluded that meetformin presents a unique opportunity for application against GC, but further clinical and mechanistic investigations are required to solidify the roles of metformin in GC. Expand
Perspectives of metformin use in endometrial cancer and other gynaecological malignancies.
The latest data on clinical use of metformin in endometrial cancer patients and potential underlying mechanisms of its activity are presented and some most important clinical information regarding met formin efficacy in other gynaecological malignancies, mainly breast and ovarian cancer is presented. Expand
The Hormetic Effect of Metformin: “Less Is More”?
The effects of MTF on T2DM on the principal target organs, such as liver, gut, adipose tissue, endothelium, heart, and skeletal muscle, are described, indicating that all organs, except the gut, accumulate MTF in the micromolar range when administered in therapeutic doses. Expand
Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation—A Special Reference to Colorectal Cancer
The mechanisms of action and resistance of immunotherapy and the types of immune checkpoint inhibitors (ICIs) as well as their correlation to gut microbiota are analyzed to present and analyze. Expand
Correlation between Expression Profiles of Key Signaling Genes in Colorectal Cancer Samples from Type 2 Diabetic and Non-Diabetic Patients
In order to gain insight into diabetes-specific modulation of colon cancer signaling, gene expression patterns of more than five hundred genes encoding signaling proteins were analyzed from colonoscopic colorectal tumor samples of type 2 diabetic and non-diabetic patients. Expand
Targeting of the tumor immune microenvironment by metformin.
The purpose of this review is to explain the basic mechanisms for the interactions and communications between immunosuppressive, anti-tumoral, and cancer cells within TME. Expand
Metformin – nichtglykämische Wirkungen
Das Biguanid Metformin ist auch nach der Einführung neuerer Antidiabetika wie der DPP-4- (Dipeptidylpeptidase 4) und der SGLT-2-Inhibitoren (SGLT-2: „sodium dependent glucose transporter 2“) derExpand
Metformin – nichtglykämische Wirkungen
Das Biguanid Metformin ist auch nach der Einführung neuerer Antidiabetika wie der DPP-4- (Dipeptidylpeptidase 4) und der SGLT-2-Inhibitoren (SGLT-2: „sodium dependent glucose transporter 2“) derExpand


Metformin as an Anticancer Agent.
Recent advances in elucidating the molecular mechanisms that are relevant for metformin use in cancer treatment are discussed. Expand
Gut microbiota and intestinal FXR mediate the clinical benefits of metformin
It is concluded that metformin acts in part through a B. fragilis–GUDCA–intestinal FXR axis to improve metabolic dysfunction, including hyperglycemia, and improves the metabolic health of humans and mice. Expand
Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect.
  • Y. Saisho
  • Medicine
  • Endocrine, metabolic & immune disorders drug targets
  • 2015
The basic and clinical evidence of the anti-inflammatory action of metformin is summarized and its clinical implication is discussed. Expand
Metformin—mode of action and clinical implications for diabetes and cancer
The updated understanding of the antigluconeogenic action of met formin in the liver and the implications of the discoveries of metformin targets for the treatment of diabetes mellitus and cancer are discussed. Expand
Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug
It is shown that metformin affected pathways with common biological functions in species from two different phyla, and many of the met formin-regulated genes in these species encoded metalloproteins or metal transporters, which provides support for the notion that altered gut microbiota mediates some of metformIn's antidiabetic effects. Expand
Metformin and reduced risk of cancer in diabetic patients
It is hypothesised that metformin use in patients with type 2 diabetes may reduce their risk of cancer and tested this hypothesis using record linkage databases developed in Tayside, Scotland: a diabetes clinical information system (DARTS) and a database of dispensed prescriptions (MEMO). Expand
The mechanisms of action of metformin
Physiologically, metformin has been shown to reduce hepatic glucose production, yet not all of its effects can be explained by this mechanism and there is increasing evidence of a key role for the gut. Expand
Metformin for Prevention and Treatment of Colon Cancer: A Reappraisal of Experimental and Clinical Data.
The available data on the capacity of antidiabetic biguanide drugs to prevent colorectal carcinogenesis and growth in vitro and in vivo in experimental models and clinical observations are presented. Expand
Diet, microorganisms and their metabolites, and colon cancer
  • S. O'keefe
  • Biology, Medicine
  • Nature Reviews Gastroenterology &Hepatology
  • 2016
The mechanisms behind microbial metabolite effects, which could be modified by diet to achieve the objective of preventing colorectal cancer in Western societies are discussed. Expand
Metformin suppresses azoxymethane‐induced colorectal aberrant crypt foci by activating AMP‐activated protein kinase
Colorectal carcinogenesis in chemical carcinogen‐induced models is examined and metformin suppresses colonic epithelial proliferation via the inhibition of the mTOR pathway through the activation of AMPK. Expand